262 related articles for article (PubMed ID: 21917824)
1. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Kaine J; Gladstein G; Strusberg I; Robles M; Louw I; Gujrathi S; Pappu R; Delaet I; Pans M; Ludivico C
Ann Rheum Dis; 2012 Jan; 71(1):38-44. PubMed ID: 21917824
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
[TBL] [Abstract][Full Text] [Related]
5. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
Keystone EC; Kremer JM; Russell A; Box J; Abud-Mendoza C; Elizondo MG; Luo A; Aranda R; Delaet I; Swanink R; Gujrathi S; Luggen M
Ann Rheum Dis; 2012 Jun; 71(6):857-61. PubMed ID: 22302417
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.
Nash P; Nayiager S; Genovese MC; Kivitz AJ; Oelke K; Ludivico C; Palmer W; Rodriguez C; Delaet I; Elegbe A; Corbo M
Arthritis Care Res (Hoboken); 2013 May; 65(5):718-28. PubMed ID: 23097311
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
[TBL] [Abstract][Full Text] [Related]
9. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous abatacept for the treatment of rheumatoid arthritis.
Schiff M
Rheumatology (Oxford); 2013 Jun; 52(6):986-97. PubMed ID: 23463804
[TBL] [Abstract][Full Text] [Related]
11. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.
Alten R; Kaine J; Keystone E; Nash P; Delaet I; Genovese MC
Arthritis Rheumatol; 2014 Aug; 66(8):1987-97. PubMed ID: 24782324
[TBL] [Abstract][Full Text] [Related]
13. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
Reggia R; Franceschini F; Tincani A; Cavazzana I
J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Schiff M; Weinblatt ME; Valente R; van der Heijde D; Citera G; Elegbe A; Maldonado M; Fleischmann R
Ann Rheum Dis; 2014 Jan; 73(1):86-94. PubMed ID: 23962455
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study.
Matsubara T; Yamana S; Tohma S; Takeuchi T; Kondo H; Kohsaka H; Ozaki S; Hashimoto H; Miyasaka N; Yamamoto A; Hiraoka M; Abe T
Mod Rheumatol; 2013 Jul; 23(4):634-45. PubMed ID: 22833376
[TBL] [Abstract][Full Text] [Related]
16. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study.
Westhovens R; Kremer JM; Emery P; Russell AS; Alten R; Barré E; Dougados M
Clin Exp Rheumatol; 2014; 32(4):553-62. PubMed ID: 25005467
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
[TBL] [Abstract][Full Text] [Related]
19. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Sibilia J; Westhovens R
Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
[TBL] [Abstract][Full Text] [Related]
20. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
